Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.
Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.